Aardvark Therapeutics

Recent Financing

Series C

Recent Raise

$85M

Aardvark Therapeutics is a San Diego-based clinical-stage biopharmaceutical company developing small-molecule TAS2R pan-agonists, including oral ARD-101 that stimulates enteroendocrine GLP-1 and CCK release for metabolic and inflammatory indications.